230 related articles for article (PubMed ID: 16431249)
21. A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy.
Hagiwara M; Yamagata K; Matsunaga T; Arakawa Y; Usui J; Shimizu Y; Aita K; Nagata M; Koyama A; Zhang B; Mastunaga A; Saku K; Saito T
Nephrol Dial Transplant; 2008 Jan; 23(1):381-4. PubMed ID: 17967799
[No Abstract] [Full Text] [Related]
22. A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy.
Mitani A; Ishigami M; Watase K; Minakata T; Yamamura T
J Atheroscler Thromb; 2011; 18(6):531-5. PubMed ID: 21325775
[TBL] [Abstract][Full Text] [Related]
23. A patient with apolipoprotein E2 variant (Q187E) without lipoprotein glomerulopathy.
Hayakawa M; Okubo M; Katori H; Nagahama K; Murase T; Kobayashi T; Tanaka S; Nakanishi K; Odawara M; Matsushita H; Yamada A
Am J Kidney Dis; 2002 Mar; 39(3):E15. PubMed ID: 11877595
[TBL] [Abstract][Full Text] [Related]
24. A novel apolipoprotein E mutation caused by a five amino acid deletion in a Chinese family with lipoprotein glomerulopathy: a case report.
Xie W; Xie Y; Lin Z; Xu X; Zhang Y
Diagn Pathol; 2019 May; 14(1):41. PubMed ID: 31092271
[TBL] [Abstract][Full Text] [Related]
25. Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3/3.
Chang CF; Lin CC; Chen JY; Yang AH; Shiao MS; Kao JT; Yang WC
Am J Kidney Dis; 2003 Sep; 42(3):E18-23. PubMed ID: 12955707
[TBL] [Abstract][Full Text] [Related]
26. Topics in lipoprotein glomerulopathy: an overview.
Saito T; Matsunaga A; Ito K; Nakashima H
Clin Exp Nephrol; 2014 Apr; 18(2):214-7. PubMed ID: 24149835
[TBL] [Abstract][Full Text] [Related]
27. Pathogenesis, histopathologic findings and treatment modalities of lipoprotein glomerulopathy: A review.
Cambruzzi E; Pêgas KL
J Bras Nefrol; 2019; 41(3):393-399. PubMed ID: 30421781
[TBL] [Abstract][Full Text] [Related]
28. Chronic graft-versus-host autoimmune disease in Fc receptor gamma chain-deficient mice results in lipoprotein glomerulopathy.
Kanamaru Y; Nakao A; Shirato I; Okumura K; Ogawa H; Tomino Y; Ra C
J Am Soc Nephrol; 2002 Jun; 13(6):1527-33. PubMed ID: 12039982
[TBL] [Abstract][Full Text] [Related]
29. Common apolipoprotein E gene mutations contribute to lipoprotein glomerulopathy in China.
Han J; Pan Y; Chen Y; Li X; Xing G; Shi J; Hou P; Zhang H; Wang H
Nephron Clin Pract; 2010; 114(4):c260-7. PubMed ID: 20090368
[TBL] [Abstract][Full Text] [Related]
30. Lipoprotein glomerulopathy in China.
Chen Y
Clin Exp Nephrol; 2014 Apr; 18(2):218-9. PubMed ID: 24165683
[TBL] [Abstract][Full Text] [Related]
31. Immunohistological localization of apolipoproteins in the glomeruli in renal disease: specifically apoB and apoE.
Sato H; Suzuki S; Kobayashi H; Ogino S; Inomata A; Arakawa M
Clin Nephrol; 1991 Sep; 36(3):127-33. PubMed ID: 1934668
[TBL] [Abstract][Full Text] [Related]
32. Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice.
Wu H; Yang J; Liu YQ; Lei S; Yang M; Yang Z; Yang Y; Hu Z
J Transl Med; 2021 Mar; 19(1):97. PubMed ID: 33663537
[TBL] [Abstract][Full Text] [Related]
33. Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by APOE mutations.
Yang M; Weng Q; Pan X; Hussain HMJ; Yu S; Xu J; Yu X; Liu Y; Jin Y; Zhang C; Li X; Ren H; Chen N; Xie J
Mol Genet Genomic Med; 2020 Aug; 8(8):e1281. PubMed ID: 32441489
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological characteristics and gene mutations in 11 patients with lipoprotein glomerulopathy.
Qin Y; Sun XJ; Hu YF; Jing M; Yu XJ; Zhao MH; Tan Y
Ren Fail; 2024 Dec; 46(1):2332491. PubMed ID: 38584145
[TBL] [Abstract][Full Text] [Related]
35. Lipoprotein glomerulopathy: first report of 2 not consanguineous Italian men from the same town.
Pasquariello A; Pasquariello G; Innocenti M; Minnei F; Funel N; Lorusso P; Barsotti G
J Nephrol; 2011; 24(3):381-5. PubMed ID: 21534236
[TBL] [Abstract][Full Text] [Related]
36. Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding.
Sam R; Wu H; Yue L; Mazzone T; Schwartz MM; Arruda JA; Dunea G; Singh AK
Am J Kidney Dis; 2006 Mar; 47(3):539-48. PubMed ID: 16490634
[TBL] [Abstract][Full Text] [Related]
37. A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I.
Takasaki S; Matsunaga A; Joh K; Saito T
CEN Case Rep; 2018 May; 7(1):127-131. PubMed ID: 29356944
[TBL] [Abstract][Full Text] [Related]
38. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy.
Ieiri N; Hotta O; Taguma Y
Am J Kidney Dis; 2003 Jan; 41(1):244-9. PubMed ID: 12500244
[TBL] [Abstract][Full Text] [Related]
39. A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy.
Tokura T; Itano S; Kobayashi S; Kuwabara A; Fujimoto S; Horike H; Satoh M; Komai N; Tomita N; Matsunaga A; Saito T; Sasaki T; Kashihara N
J Atheroscler Thromb; 2011; 18(6):536-41. PubMed ID: 21467726
[TBL] [Abstract][Full Text] [Related]
40. Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice.
Atkinson RD; Coenen KR; Plummer MR; Gruen ML; Hasty AH
Am J Physiol Endocrinol Metab; 2008 Feb; 294(2):E284-90. PubMed ID: 18029445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
